by The Mount Sinai Hospital
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.
The … Read more
Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider watching the recording of the OC Education webinar, “But This is Different: Understanding and Getting Support for the Unique Needs of People … Read more
by Lauren Comander
Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is
… Read moreby Jax DiEugenio
Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more
Clearity’s Perspective: This article is written by a daughter whose mother was diagnosed with advanced ovarian cancer. She shares the story of her mother’s diagnosis and treatment and how her family handled learning of her mother’s inheritable genetic condition. Clearity
As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
by Josh Friedman
An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian … Read more
— About half of patients responded, duration of response as long as 19 months in three trials
By Charles Bankhead
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more
By Ryan Scott
Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more
Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more
By Kristi Rosa
Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more
Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,
… Read moreBy Mark Fuerst
About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more
A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already … Read more
By Fay Lin, PhD
A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic … Read more
By Ashling Wahner
Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more
Clearity’s Perspective: In the January 17, 2024 update to the National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer, several new therapies have been added to the list of acceptable regimens for recurrent platinum-resistant ovarian cancer. For example, trastuzumab deruxtecan … Read more
By James H. Doroshow, M.D.
More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision
… Read moreBy Andrea Anderson
NEW YORK – An Italian team led by investigators at Humanitas University has come up with a test for detecting early-stage high-grade serous ovarian cancer (HGSOC) that relies on DNA sequencing of cervical smear samples collected during … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
